- Home
- MIRM vs SOC Comparison
MIRM vs SOC Comparison
Compare MIRM & SOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SOC
- Stock Information
- Founded
- MIRM 2018
- SOC 2020
- Country
- MIRM United States
- SOC United States
- Employees
- MIRM N/A
- SOC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SOC
- Sector
- MIRM Health Care
- SOC
- Exchange
- MIRM Nasdaq
- SOC Nasdaq
- Market Cap
- MIRM 2.1B
- SOC 2.2B
- IPO Year
- MIRM 2019
- SOC N/A
- Fundamental
- Price
- MIRM $46.95
- SOC $24.52
- Analyst Decision
- MIRM Strong Buy
- SOC Buy
- Analyst Count
- MIRM 11
- SOC 3
- Target Price
- MIRM $57.00
- SOC $25.00
- AVG Volume (30 Days)
- MIRM 450.2K
- SOC 1.3M
- Earning Date
- MIRM 02-26-2025
- SOC 02-20-2025
- Dividend Yield
- MIRM N/A
- SOC N/A
- EPS Growth
- MIRM N/A
- SOC N/A
- EPS
- MIRM N/A
- SOC N/A
- Revenue
- MIRM $307,028,000.00
- SOC N/A
- Revenue This Year
- MIRM $82.14
- SOC N/A
- Revenue Next Year
- MIRM $26.18
- SOC $606.07
- P/E Ratio
- MIRM N/A
- SOC N/A
- Revenue Growth
- MIRM 112.14
- SOC N/A
- 52 Week Low
- MIRM $23.14
- SOC $10.11
- 52 Week High
- MIRM $48.89
- SOC $28.67
- Technical
- Relative Strength Index (RSI)
- MIRM 65.98
- SOC 58.21
- Support Level
- MIRM $40.55
- SOC $21.76
- Resistance Level
- MIRM $47.25
- SOC $25.22
- Average True Range (ATR)
- MIRM 1.49
- SOC 1.21
- MACD
- MIRM 0.56
- SOC 0.11
- Stochastic Oscillator
- MIRM 95.52
- SOC 74.19
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.